DLDorine Van Loo

Dorine Van Loo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dorine Van Loo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative effectiveness of oral appliances and continuous positive airway pressure: a prospective non-randomized study using a non-inferiority framework

    by Marijke Dieltjens, Sanne Engelen, Ali Azarbarzin, Karlien Van Den Bossche, Dorine Van Loo, Marc J Braem, Renilde Goossens, Johan Verbraecken, Sara Op de Beeck, Olivier M Vanderveken

    Rationale: Continuous positive airway pressure (CPAP) is the first‑line treatment for moderate-to-severe obstructive sleep apnea (OSA), while mandibular advancement devices (MAD) are an established alternative for CPAP-intolerant patients. Differences in efficacy and adherence may affect overall clinical effectiveness. Objectives: This prospective non-randomized study (First Line Obstructive Sleep Apnea Treatment (FLOSAT)) evaluated the clinical effectiveness of MAD therapy as first-line treatment option compared to second-line CPAP therapy. Methods: Moderate-to-severe OSA patients received three months of MAD therapy, followed by a wash-out period and three months of CPAP therapy. The primary outcome was mean disease alleviation (MDA), a measure combining efficacy and adherence, analyzed using a modified intention-to-treat approach. Measurement and Main Results: Ninety-four patients (86% male, age: 52±12 years, body mass index: 28·1±3·4 kg/m2) were included. The averaged individual MDA was 49·9±26·1% with MAD and 49·1±34·5% with CPAP, demonstrating non-inferiority of MAD compared to CPAP (p = 0·4). The apnea/hypopnea index (AHI) decreased significantly from 24·2(18·1; 32·3)/h at baseline to 8·4(5·4; 12·9)/h with MAD and to 4·1(2·2; 11·5)/h with CPAP (both p < 0·001). Nightly adherence was significantly higher with MAD (6·7(5·2;7·3) hours/night) than with CPAP (5·4(2·0;6·5); p < 0·05). In this study, 51% of patients preferred MAD compared to 42% for CPAP Conclusions: MAD therapy achieved good efficacy and high adherence, resulting in non-inferior effectiveness compared to CPAP. However, the sequential, non-randomized design limits interpretation because treatment effects cannot be separated from potential order or period effects. Furthermore, MDA has not been validated against patient-important outcomes and therefore does not establish clinical non-inferiority.


  • Open Access

    Association between respiration-synchronized hypoglossal nerve stimulation and changes in sleep apnea-specific hypoxic burden in patients with obstructive sleep apnea

    by Dorine Van Loo, Marijke Dieltjens, Johan Verbraecken, Ali Azarbarzin, Sara Op de Beeck, Olivier M Vanderveken


  • Open Access

    Recent Advancements in the Clinical Pathway of Respiration-Synchronized Hypoglossal Nerve Stimulation Therapy for Obstructive Sleep Apnea

    by Dorine Van Loo, Eldar Tukanov, Marijke Dieltjens, Sara Op de Beeck, Eli Van de Perck, Johan Verbraecken, Olivier M. Vanderveken

    Background: Respiration-synchronized hypoglossal nerve stimulation (HGNS) is an effective treatment option for selected patients with obstructive sleep apnea (OSA). While literature on the standardization of the post-implant care pathway for patients treated with HGNS therapy remains limited, the growing global use of HGNS has made structured post-implant care management increasingly important. Methods: This narrative review summarizes the advancements related to the clinical pathway for respiration-synchronized HGNS therapy over the past 5 years, with a special focus on post-implant care management. Results: Selection criteria for respiration-synchronized HGNS are changing as new clinical findings emerge, including both anatomical and non-anatomical markers. Evidence suggests that adopting single-amplitude, full-night sleep testing may provide a more reliable assessment of HGNS treatment efficacy. Several studies have described optimization strategies for patients with suboptimal HGNS therapy response or therapy-related discomfort, including the use of awake endoscopy and drug-induced sleep endoscopy for advanced HGNS programming and the use of combination therapy, although data remains limited. Conclusions: The clinical care pathway for respiration-synchronized HGNS continues to evolve, including patient selection, evaluation of treatment success, and strategies for managing incomplete responders or patients with therapy-related discomfort. Nonetheless, addressing insufficient treatment responses remains a significant challenge and a key area for future research and clinical optimization.

  • Open Access

    Baseline Characteristics Associated with Hypoglossal Nerve Stimulation Treatment Outcomes in Patients with Obstructive Sleep Apnea: A Systematic Review

    by Eldar Tukanov, Dorine Van Loo, Marijke Dieltjens, Johan Verbraecken, Olivier M. Vanderveken, Sara Op de Beeck

    Hypoglossal nerve stimulation (HGNS) has emerged as an effective treatment for obstructive sleep apnea (OSA). Identifying baseline characteristics that prospectively could predict treatment outcomes even better is crucial for optimizing patient selection and improving therapeutic success in the future. A systematic review was conducted following PRISMA guidelines. Literature searches in Medline, Web of Science, and Cochrane databases identified studies assessing baseline characteristics associated with HGNS treatment outcomes. Inclusion criteria focused on studies with adult patients diagnosed with OSA, treated with HGNS, and assessed using full-night efficacy sleep studies. Risk of bias was evaluated using the NICE tool. Twenty-six studies met the inclusion criteria. Commonly reported baseline characteristics with predictive potential included BMI, site of collapse, and various pathophysiological endotypes. Most studies used the original Sher criteria to define treatment response, though variations were noted. Results suggested that lower BMI, absence of complete concentric collapse at the palatal level, and specific pathophysiological traits were associated with better HGNS outcomes. This review identified several baseline characteristics associated with HGNS outcomes, which may guide future patient selection. Importantly, patients were already preselected for HGNS. Standardizing response criteria is recommended to enhance the evaluation and effectiveness of HGNS therapy in OSA patients.


  • Open Access

    Personalized Treatment for Obstructive Sleep Apnea: Beyond CPAP

    by Margot Van Daele, Yannick Smolders, Dorine Van Loo, Charlotte Bultynck, Johan Verbraecken, Anneclaire Vroegop, Thérèse Lapperre, Sara Op de Beeck, Marijke Dieltjens, Olivier M. Vanderveken

    Obstructive sleep apnea (OSA) is a sleep disorder characterized by repetitive episodes of partial or complete obstruction of the upper airway during sleep. Continuous positive airway pressure (CPAP) is a method used as a first-line treatment for obstructive sleep apnea (OSA). However, intolerance and resistance to CPAP can limit its long-term effectiveness. Alternative treatments are available, such as Mandibular Advancement Devices (MADs), positional therapy, upper airway surgery, and maxillomandibular osteotomy. However, often less efficient in reducing the apnea-hypopnea index, the higher tolerance of and compliance to alternative treatment has resulted in the adequate treatment of OSA in CPAP-intolerant patients. This paper describes the protocol of a prospective single-center cohort study including adult patients with moderate to severe OSA (15 events/h ≤ apnea-hypopnea index (AHI) < 65 events/h) that failed to comply with CPAP therapy. Selected patients will be invited to the clinic to explore alternative treatment options where DISE will be a first step in further identifying upper airway collapse during sleep. By exploring alternative treatment options in CPAP-intolerant patients and systematically documenting their treatment paths, an algorithm can be defined to better guide patients towards personalized treatment for OSA. The follow-up is aimed at 5 years with an inclusion of 170 patients per year, including a drop-out rate of 15%. By leveraging a real-world database, this study aims to bridge the gap between research and clinical practice, facilitating the development of evidence-based guidelines and personalized treatment algorithms for CPAP-intolerant patients.


  • Open Access

    Acetazolamide as an Add-on Therapy Following Barbed Reposition Pharyngoplasty in Obstructive Sleep Apnea: A Randomized Controlled Trial

    by Simon Hellemans, Eli Van de Perck, Dorine Van Loo, Johan Verbraecken, Scott A. Sands, Ali Azarbarzin, Marijke Dieltjens, Sara Op De Beeck, Anneclaire Vroegop, Olivier M. Vanderveken

    Surgical interventions, like barbed reposition pharyngoplasty (BRP), are a valuable alternative for patients with obstructive sleep apnea (OSA) who are unable to tolerate continuous positive airway pressure (CPAP). However, predicting surgical success remains challenging, partly due to the contribution of non-anatomical factors. Therefore, combined medical treatment with acetazolamide, known to stabilize respiratory drive, may lead to superior surgical results. This double-blind, parallel-group randomized controlled trial evaluates the efficacy of acetazolamide as an add-on therapy to BRP in OSA. A total of 26 patients with moderate to severe OSA undergoing BRP were randomized to receive either acetazolamide or placebo post-surgery for 16 weeks. The group who was treated with BRP in combination with acetazolamide showed a reduction in AHI of 69.4%, significantly surpassing the 32.7% reduction of the BRP + placebo group (p < 0.01). The sleep apnea-specific hypoxic burden also decreased significantly in the group who was treated with BRP + acetazolamide (p < 0.01), but not in the group receiving BRP + placebo (p = 0.28). Based on these results, acetazolamide as an add-on therapy following BRP surgery shows promise in improving outcomes for OSA patients, addressing both anatomical and non-anatomical factors.


  • Open Access

    Hypoglossal Nerve Stimulation Therapy in a Belgian Cohort of Obstructive Sleep Apnea Patients

    by Dorine Van Loo, Marijke Dieltjens, Sanne Engelen, Johan Verbraecken, Olivier M. Vanderveken

    Hypoglossal nerve stimulation (HGNS) has emerged as a widespread and innovative treatment option for selected moderate-to-severe obstructive sleep apnea (OSA) patients who cannot be treated effectively with traditional treatment modalities. In this observational cohort study, the objective and subjective outcomes of Belgian OSA patients treated with HGNS therapy were analyzed at 6 and 12 months post-implantation. Thirty-nine patients implanted with a respiration-synchronized HGNS device at the Antwerp University Hospital w ere included in this study. Patients underwent baseline in-laboratory polysomnography and a follow-up sleep study 6 and 12 months post-implantation. Questionnaires on patient experience and daytime sleepiness were filled out and data on objective therapy usage were collected. All 39 patients completed the 6-month follow-up and 21 patients (54%) completed the 12-month follow-up. Median AHI decreased from 33.8 [26.1;45.0] to 10.2 [4.8;16.4] at the 6-month follow-up, and to 9.6 [4.1;16.4] at the 12-month follow-up (p < 0.001). The surgical success rate, according to the Sher20 criteria, was 80% and 76% at the 6- and 12-month follow-ups, respectively. Median ESS improved from 12.0 [7.0;18.0] at baseline to 6.0 [2.5;11.0] at 6 months (p < 0.001) and to 6.5 [2.8;11.5] at 12 months (p = 0.012). Objective therapy usage was 7.4 [6.6;8.0] and 7.0 [5.9:8.2] h/night at the 6- and 12-month follow-ups, respectively. A high overall clinical effectiveness of HGNS therapy, as shown by a mean disease alleviation of 58%, was demonstrated at 12 months post-implantation. Overall, HGNS therapy using respiration-synchronized neurostimulation of the XII cranial nerve resulted in a significant improvement in both objective and subjective OSA outcomes, with a high level of patient satisfaction and high treatment adherence.